Perseus Proteomics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

RaQualia Pharma, Inc.

Wakamoto Pharmaceutical Co., Ltd.

Perseus Proteomics, Inc.

Solasia Pharma KK

Nippon Chemiphar Co., Ltd.

Pharmarise Holdings Corp.

D. Western Therapeutics Institute, Inc.

Renascience, Inc.

BrightPath Biotherapeutics Co., Ltd.

SymBio Pharmaceuticals Ltd.

Delta-Fly Pharma, Inc.

Why is Perseus Proteomics, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE

Poor long term growth as Net Sales has grown by an annual rate of 18.73% and Operating profit at -34.81% over the last 5 years

With a growth in Net Sales of 12.4%, the company declared Outstanding results in Dec 25

DEBT-EQUITY RATIO (HY) Lowest at -139.69 %
RAW MATERIAL COST(Y) Fallen by -0.93% (YoY)
NET SALES(Q) Highest at JPY 42.14 MM

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -74.50%, its profits have risen by 5.6%

Underperformed the market in the last 1 year

Even though the market (Japan Nikkei 225) has generated returns of 40.96% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -74.50% returns

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Perseus Proteomics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Perseus Proteomics, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Perseus Proteomics, Inc.

-100.0%

-0.35

67.86%

Japan Nikkei 225

41.2%

1.44

28.42%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

18.73%

EBIT Growth (5y)

-34.81%

EBIT to Interest (avg)

-725.94

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.16

Sales to Capital Employed (avg)

0.07

Tax Ratio

0.27%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.63

EV to EBIT

-5.98

EV to EBITDA

-6.01

EV to Capital Employed

-21.08

EV to Sales

41.25

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-58.10%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

19What is working for the Company

DEBT-EQUITY RATIO (HY)

Lowest at -139.69 %

RAW MATERIAL COST(Y)

Fallen by -0.93% (YoY

NET SALES(Q)

Highest at JPY 42.14 MM

OPERATING PROFIT(Q)

Highest at JPY -173.52 MM

OPERATING PROFIT MARGIN(Q)

Highest at -411.78 %

PRE-TAX PROFIT(Q)

Highest at JPY -163.74 MM

NET PROFIT(Q)

Highest at JPY -164.22 MM

EPS(Q)

Highest at JPY -11.42

-2What is not working for the Company

ROCE(HY)

Lowest at -60.08%

Here's what is working for Perseus Proteomics, Inc.

Net Sales

At JPY 42.14 MM has Grown at 38.22%

over average net sales of the previous four periods of JPY 30.49 MM

MOJO Watch

Near term sales trend is very positive

Net Sales (JPY MM)

Debt-Equity Ratio

Lowest at -139.69 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales

Highest at JPY 42.14 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Operating Profit

Highest at JPY -173.52 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (JPY MM)

Operating Profit Margin

Highest at -411.78 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Pre-Tax Profit

Highest at JPY -163.74 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (JPY MM)

Net Profit

Highest at JPY -164.22 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (JPY MM)

EPS

Highest at JPY -11.42

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (JPY)

Raw Material Cost

Fallen by -0.93% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales